Transmission of antiretroviral-drug-resistant HIV-1 variants

Lancet

Volumn 354, Issue 9180, 1999, Pages 729-733

  Yerly, S ^a   Kaiser, L ^a   Race, E ^b   Bru, J P ^c   Clavel, F ^b   Perrin, L ^a  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b BICHAT HOSPITAL   (France)

^c Centre Hospitalier de la Region d'Annecy   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESISTANCE; FEMALE; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; SCREENING TEST; VIRUS RECOMBINANT; VIRUS TRANSMISSION;

EID: 0033612928     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)12262-6     Document Type: Article

References (26)

1. Hirsch M.S., Conway B., D'Aquila R.T.et al. Antiretroviral drug resistance testing in adults with HIV infection. JAMA. 279:1998;1984-1991.
2. Coffin J.M. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science. 267:1995;483-489.
3. Havlir D.V., Eastman S., Gamst A., Richman D.D. Nevirapine-resistant human immunodeficiency virus: kinetics of replication and estimated prevalence in untreated patients. J Virol. 70:1996;7894-7899.
4. ®) in Switzerland, Australia and the United States between 1988 and 1994. AIDS Res Hum Retroviruses. 11(suppl 1):1995;S162. abstr.
5. Yerly S., Rakik A., Kinloch-de Loës S.et al. Prévalence de la transmission de virus résistant à la zidovudine en Suisse. Schweiz Med Wochenschr. 126:1996;1845-1848.
6. Imrie A., Beveridge A., Genn W., Vizzard J., Cooper D.A. Transmission of human immunodeficiency virus type 1 resistant to nevirapine and zidovudine. Sydney Primary HIV Infection Study Group. J Infect Dis. 175:1997;1502-1505.
7. Hecht F.M., Grant R.M., Petropoulos C.J.et al. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors. N Engl J Med. 339:1998;307-311.
8. Lorenzi P., Opravil M., Hirschel B.et al. Impact of drug resistance mutations on virologic response to salvage therapy. AIDS. 13:1999;F17-21.
9. Eron J., Falloon J., Masur H.et al. Activity of combination abacavir/amprenavir/efavirenz therapy in HIV-1-infected subjects failing their current protease inhibitor-containing regimen. AIDS. 12(suppl 4):1998;S13. abstr.
10. Hammer S.M., Squires K.E., Hughes M.D.et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med. 337:1997;725-733.
11. Montaner J.S., Reiss P., Cooper D.et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial - Italy, The Netherlands, Canada and Australia Study. JAMA. 279:1998;930-937.
12. Grant R.M., Hecht F.M., Petropoulos C.J.et al. Transmission of HIV-1 resistant to multiple reverse transcriptase and protease inhibitors: International Workshop on HIV Drug Resistance Treatment Strategies and Eradication. Lake Maggiore, Italy, June 1998. Antiviral Ther. 3(suppl 1):1998;108. abstr.
13. Kinloch-de Loës S., de Saussure P., Saurat J.H., Stalder H., Hirschel B., Perrin L. Symptomatic primary infection due to human immunodeficiency virus type 1: review of 31 cases. Clin Infect Dis. 17:1993;59-65.
14. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 187:1987;156-159.
15. Charneau P., Mirambeau G., Roux P., Paulos S., Buc H., Clavel F. HIV-1 reverse transcription: a termination step at the center of the genome. J Mol Biol. 241:1994;651-662.
16. Zennou V., Mammano F., Paulous S., Mathez D., Clavel F. Loss of viral fitness associated with multiple Gag and Gag-Pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo. J Virol. 72:1998;3300-3306.
17. Schinazi R.F., Larder B.A., Mellors J. Resistance table: mutations in retroviral genes associated with drug resistance. Int Antiviral News. 5:1997;129-142.
18. Roberts N.A., Craig J.C., Sheldon J. Resistance and cross-resistance with saquinavir and other protease inhibitors: theory and practice. AIDS. 12:1998;453-460.
19. Havlir D.V., Marschner I.C., Hirsch M.S.et al. Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy. N Engl J Med. 339:1998;1261-1268.
20. Miller V., Philips A., Rottmann C.et al. Dual resistance to zidovudine and lamivudine in patients treated with zidovudine-lamivudine combination: association with therapy failure. J Infect Dis. 177:1998;1521-1532.
21. Schuurman R., Nijhuis M., van Leeuwen R.et al. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis. 171:1995;1411-1419.
22. Bock N.K., Nijhuis M., Keulen W.et al. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. EMBO J. 15:1996;4040-4049.
23. Condra J.H., Schleif W.A., Blahy O.M.et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature. 374:1995;569-571.
24. Learn G.H., Korber B.T., Foley B.et al. Maintaining the integrity of human immunodeficiency virus sequence databases. J Virol. 70:1996;5720-5730.
25. Gebhardt M., Rickenbach M., Egger M. Impact of antiretroviral combination on AIDS surveillance reports in Switzerland. AIDS. 12:1998;1195-1201.
26. Perrin L., Schockmel G.A., Fagard C., et al. Suppression of viremia and immune reconstitution in seroconverting patients receiving triple antiviral therapy. 12th World AIDS Conference, Geneva, July, 1998 (abstr 12191).